These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16336515)

  • 1. In vitro and in vivo models for testing arrhythmogenesis in drugs.
    Carlsson L
    J Intern Med; 2006 Jan; 259(1):70-80. PubMed ID: 16336515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.
    Carlsson L
    Pharmacol Ther; 2008 Aug; 119(2):160-7. PubMed ID: 18558435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
    Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
    Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA; Su Z; Martin RL; Cox BF
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
    Wang D; Patel C; Cui C; Yan GX
    Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.
    Takahara A; Sugiyama A; Hashimoto K
    Br J Pharmacol; 2005 Oct; 146(4):561-7. PubMed ID: 16056235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.
    Thomsen MB; Matz J; Volders PG; Vos MA
    Pharmacol Ther; 2006 Oct; 112(1):150-70. PubMed ID: 16714061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.
    Webster R; Leishman D; Walker D
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):116-26. PubMed ID: 11865665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced prolongation of the QT interval.
    Cruciani RA; Portenoy RK; Homel P
    N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208786
    [No Abstract]   [Full Text] [Related]  

  • 17. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK; Hancox JC; Curtis MJ
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
    Tabo M; Kimura K; Ito S
    J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced q-T prolongation.
    Kao LW; Furbee RB
    Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.